Impact of the LDL subfraction phenotype on Lp-PLA2 distribution, LDL modification and HDL composition in type 2 diabetes

Effect of Improving Glycemic Control in Patients With Type 2 Diabetes Mellitus on Low-Density Lipoprotein Size, Electronegative Low-Density Lipoprotein and Lipoprotein-Associated Phospholipase A2 Distribution

(2012) José L. Sánchez-Quesada et al.   AMERICAN JOURNAL OF CARDIOLOGY

The impact of serum lipids on risk for microangiopathy in patients with type 2 diabetes mellitus

(2012) Peter P Toth et al.   Cardiovascular Diabetology

Lipoprotein-Associated Phospholipase A2 Mass and Activity and Risk of Cardiovascular Disease in a Population With High Prevalences of Obesity and Diabetes: The Strong Heart Study

(2012) J. R. Kizer et al.   DIABETES CARE

Lipoprotein-Associated Phospholipase A2(Lp-PLA2) and Future Risk of Type 2 Diabetes: Results from the Cardiovascular Health Study

(2012) T. L. Nelson et al.   JOURNAL OF CLINICAL ENDOCRINOLOGY & METABOLISM

Modulation of oxidative stress, inflammation, and atherosclerosis by lipoprotein-associated phospholipase A2

(2012) Robert S. Rosenson et al.   JOURNAL OF LIPID RESEARCH

Lipoprotein-Associated Phospholipase A2 Bound on High-Density Lipoprotein Is Associated With Lower Risk for Cardiac Death in Stable Coronary Artery Disease Patients

(2012) Loukianos S. Rallidis et al.   JOURNAL OF THE AMERICAN COLLEGE OF CARDIOLOGY

Genetic Modulation of Lipid Profiles following Lifestyle Modification or Metformin Treatment: The Diabetes Prevention Program

(2012) Toni I. Pollin et al.   PLoS Genetics

Biological activities of HDL subpopulations and their relevance to cardiovascular disease

(2011) Laurent Camont et al.   TRENDS IN MOLECULAR MEDICINE

Lp-PLA2 as a Marker of Cardiovascular Diseases

(2010) Sabha Bhatti et al.   Current Atherosclerosis Reports

Antiatherogenic function of HDL particle subpopulations: focus on antioxidative activities

(2010) Anatol Kontush et al.   CURRENT OPINION IN LIPIDOLOGY

Lipoprotein-Associated Phospholipase A2 Activity and Incident Coronary Heart Disease Among Men and Women With Type 2 Diabetes

(2010) I. J. Hatoum et al.   DIABETES

Small-dense LDL and LDL glycation in metabolic syndrome and in statin-treated and non-statin-treated type 2 diabetes

(2010) Nahla N Younis et al.   Diabetes & Vascular Disease Research

Lipoprotein-associated phospholipase A2 and future risk of subclinical disease and cardiovascular events in individuals with type 2 diabetes: the Cardiovascular Health Study

(2010) T. L. Nelson et al.   DIABETOLOGIA

HDL-associated factors provide additional prognostic information for coronary artery disease as determined by multi-detector row computed tomography

(2009) Ryoko Mitsutake et al.   INTERNATIONAL JOURNAL OF CARDIOLOGY

Lipoprotein-Associated and Secretory Phospholipase A2 in Cardiovascular Disease: The Epidemiological Evidence

(2008) Wolfgang Koenig et al.   CARDIOVASCULAR DRUGS AND THERAPY

Glycation as an atherogenic modification of LDL

(2008) Nahla Younis et al.   CURRENT OPINION IN LIPIDOLOGY